| Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. | |
| | |
MedLine Citation:
|
PMID: 23153963 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Antibiotic therapy for complicated intra-abdominal infections (cIAIs) should provide broad-spectrum coverage both Gram-positive and Gram-negative microorganisms. The PROMISE study compared the clinical and bacteriological efficacy and safety of moxifloxacin versus ertapenem for the treatment of cIAIs. This randomised, prospective, double-dummy, double-blind, multicentre trial was designed as a non-inferiority study. The safety and efficacy of 5-14 days of daily intravenous moxifloxacin (400mg) or ertapenem (1g) were compared in patients with cIAIs requiring surgery and parenteral antibiotic therapy. The primary and secondary endpoints included clinical and bacteriological responses at 21-28 days after the end of treatment (TOC), respectively. Of 830 enrolled patients, 699 were efficacy valid. Moxifloxacin was non-inferior to ertapenem regarding clinical success [89.5% (315/352) versus 93.4% (324/347); 95% confidence interval (CI) -7.9%, 0.4%]. There were no significant differences between groups for any of the primary causes or types of cIAI regarding clinical response. Bacteriological success was achieved in 86.5% (257/297) of moxifloxacin-treated patients and 90.2% (249/276) of ertapenem-treated patients (95% CI -9.0%, 1.5%). There were no major differences between groups regarding the frequency or types of organisms eradicated. The incidence of adverse events (AEs) was higher with moxifloxacin than ertapenem (P=0.039), however a similar number of drug-related AEs was seen in each group (P=1.000). Wound infections, nausea and increased lipase were the most commonly reported AEs with both agents. The results show that moxifloxacin is a valuable treatment option for a range of community-acquired cIAIs with mild-to-moderate severity [Clinical Trials.gov Identifier: NCT00492726]. |
| | |
Authors:
|
J J De Waele; J M Tellado; J Alder; P Reimnitz; M Jensen; B Hampel; P Arvis |
Related Documents
:
|
23151713 - Therapeutic extraction of lower incisor for orthodontic treatment. 23400573 - Quantification of leishmania infantum kinetoplast dna for monitoring the response to me... 19505883 - Surface electrocardiogram to predict outcome in candidates for cardiac resynchronizatio... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-12 |
Journal Detail:
|
Title: International journal of antimicrobial agents Volume: - ISSN: 1872-7913 ISO Abbreviation: Int. J. Antimicrob. Agents Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111860 Medline TA: Int J Antimicrob Agents Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
Affiliation:
|
Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium. Electronic address: Jan.DeWaele@UGent.be. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ?-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients wit...
Next Document: Basal ganglia-cortical interactions in Parkinsonian patients.